Marten D. Visser

Leiden, ZH 2300RA, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

It is urgent that pesticide authorisation learns from reality.

It is urgent that pesticide authorisation learns from reality.

Journal: Environment international

Published: January 11, 2026

Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.

Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 23, 2024

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.

Journal: Journal for immunotherapy of cancer

Published: October 17, 2023

Neoantigen Targetability in Progressive Advanced Melanoma.

Neoantigen Targetability in Progressive Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 26, 2023

Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.

Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.

Journal: Journal for immunotherapy of cancer

Published: February 02, 2022

Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.

Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment.

Journal: Ophthalmology science

Published: August 19, 2021

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia.

Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: December 28, 2020

Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.

Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.

Journal: BMJ open

Published: November 25, 2020

Simplified Monopalmitoyl Toll-like Receptor 2 Ligand Mini-UPam for Self-Adjuvanting Neoantigen-Based Synthetic Cancer Vaccines.

Simplified Monopalmitoyl Toll-like Receptor 2 Ligand Mini-UPam for Self-Adjuvanting Neoantigen-Based Synthetic Cancer Vaccines.

Journal: Chembiochem : a European journal of chemical biology

Published: October 04, 2020

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.

Journal: Journal for immunotherapy of cancer

Published: February 17, 2020

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.

Journal: Genome medicine

Published: July 22, 2019

Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.

Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.

Journal: Familial cancer

Published: June 17, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026